Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173299 | 0.86 | GRM5 (0.75) | GRM5CYP2C9 | |
| SCHEMBL170553 | 0.84 | GRM5 (0.73) | GRM5CYP2C9 | |
| SCHEMBL16937455 | 0.83 | GRM5 (0.71) | GRM5CYP2C9 | |
| SCHEMBL158870 | 0.81 | GRM5 (0.68) | GRM5CYP2C9 | |
| SCHEMBL173370 | 0.81 | GRM5 (1.00) | GRM5CYP2C9DRD2DRD3 | |
| SCHEMBL157286 | 0.81 | GRM5 (0.69) | GRM5CYP2C9 | |
| SCHEMBL173881 | 0.80 | GRM5 (0.67) | GRM5CYP2C9 | |
| SCHEMBL15293376 | 0.80 | GRM5 (0.73) | GRM5CYP2C9 | |
| SCHEMBL156930 | 0.80 | GRM5 (0.80) | GRM5CYP2C9 | |
| SCHEMBL155133 | 0.80 | GRM5 (0.66) | GRM5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2611298-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM1 | GRM5 1/4885CYP2C9 3078/4885DRD2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.